Form 4 ARROWHEAD PHARMACEUTICAL For: Feb 07 Filed by: Anzalone Christopher Richard
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
February 11, 2025 7:46 AM ESTChardan Capital Markets analyst Keay Nakae reiterated a Buy rating and $60.00 price target on Arrowhead Pharma (NASDAQ: ARWR)
The analyst comments "The company is currently evaluating plozasiran in three other phase III studies: SHASTA-3 and SHASTA-4 in adults with SHTG (currently enrolling), and MUIR-3 in adults... More
